Enterprise Value
649.3M
Cash
192.5M
Avg Qtr Burn
-35.92M
Short % of Float
28.46%
Insider Ownership
21.61%
Institutional Own.
85.31%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
INBRX-101 (AAT-Fc fusion protein) Details Genetic disorder, Severe alpha-1 antitrypsin deficiency, Rare genetic disease, Emphysema due to Alpha-1 Antitrypsin Deficiency | Phase 2 Data readout | |
INBRX-109 (DR5 agonist) Details Solid tumor/s, Cancer, Chondrosarcoma | Phase 2 Data readout | |
INBRX-109 (DR5 agonist) Details Relapsed/refractory Ewing sarcoma | Phase 1 Data readout | |
INBRX-106 (OX40 agonist) +/- Keytruda Details Solid tumor/s, Cancer | Phase 1 Data readout | |
INBRX-105 (PDL1 X 4-1BB tetravalent conditional agonist) +/- Keytruda Details Solid tumor/s, Cancer | Phase 1 Data readout |